

Remarks

This is in response to the Official Action of December 8, 2004. Reconsideration in light of the remarks below is respectfully requested.

1. Section 112 rejections.

Claims 11-12, 14-17, 19-22, 24-27 and 29-30 stand rejected as lacking enablement under the first paragraph of 35 USC 112. Reconsideration is respectfully requested in light of the following comments on the *Wands* factors set forth in the Official Action.

With respect to "the nature of the invention", it is submitted that the invention is a "method of treatment". It is submitted that methods of treatment are well-settled subject matter, that the level of skill in the art of pharmaceutical sciences is high, and that, where an invention has been described as a method, such characterization has been considered a *Wands* factor favoring the grant of generic claims.

No mention in the official action is made of "the level of skill in the pertinent art". Level of skill must also be considered in evaluating enablement under the *Wands* line of cases. In this case the level of skill in the art is high and this factor weights in favor of the applicants.

"State of the art", another *Wands* factor, is consolidated with "the predictability or lack thereof in the art." Applicant respectfully objects. "State of the art" is characterized **separately** from "predictability of the art" under the *Wands* line of cases. In this case, the "state of the art" is highly developed, as reflected by (among other things) the numerous issued United States patents on the therapeutic use of antibodies and the broad commercial availability of techniques for "humanizing" antibodies for therapeutic purposes, all as discussed extensively in the instant specification.

Likewise, in addressing "predictability of the art", the official action relies upon the problems with rodent or unmodified antibodies. However, the claims are not so limited. Techniques for "humanizing" antibodies were widely available at the time the instant application was filed, are discussed extensively in the instant specification, and persons skilled in the art would readily know how to "humanize" antibodies for use in the

instant invention through routine product development procedures. Accordingly, this factor weights in favor of applicants.

With respect to "guidance in the specification", persons skilled in the art would be able to readily arrive at a pharmaceutical formulation and dosage for carrying out the present invention with the exercise of routine skill. As noted above, the specification provides extensive discussion of the humanization of antibodies, all of which can be carried out in accordance with routine skill.

While the official action is critical of the number of working examples, it is noted that the number of working examples alone, even in cases involving *ex vivo* therapeutic immunology, does not negate enablement. *See, e.g., In re Strahilevitz*, 212 USPQ 561 (CCPA 1982)(finding of lack of enablement for immunological method for removing a hapten from the blood of a mammal reversed).

While the claims presented are indeed generic, it is respectfully submitted that scope of the claims alone should not negate enablement where, as here, the remaining *Wands* factors weigh in favor of the grant of generic protection.

The present inventors made a noteworthy discovery: That the endothelial cell surface ATP synthase is active in ATP synthesis and is inhibited by angiostatin. *See, e.g., T Moser et al., Proc. Natl. Acad. Sci. USA 98; 6656-6661 (June 5, 2001)(copy enclosed).* From this noteworthy discovery and the teaching of the instant specification, the claimed invention can be readily applied through the exercise of routine skill. Accordingly, it is respectfully requested that the *Wands* factors be reevaluated in light of the comments above, and respectfully submitted that this rejection should be withdrawn.

2. Section 102 rejections.

Claims 48-52 stand rejected as anticipated under 35 USC 102(b) by **Dunn et al.** This rejection is respectfully traversed.

Dunn et al. uses an *Escherichia coli* ATPase which is only about sixty percent homologous to human ATPase. Given this dissimilarity, the skilled biochemist would not expect an antibody that bound to *E. Coli* ATPase to also bind to a human ATPase.

Dunn et al. only determined the activity of antibody in interfering with the activity

of enzyme in breaking down ATP, that is, as an ATPase, and not as an ATP synthase.

Dunn et al. only determined the activity of their antibody on membrane bound bacterial mitochondrial ATPase or plant chloroplast ATPase. they found that the enzyme was less active when membrane bound than the solubilized enzyme, apparently due to the different environment. Therefore Dunn et al. show that the activity of the antibody in affecting enzyme activity is highly dependent upon the environment in which the enzyme is found. The skilled biochemist would thus further doubt that the antibodies of Dunn et al. would have the properties of the claimed antibodies.

§ 2112 of the MPEP states that, when (as here) a recited feature of a claim is not expressly stated in the prior art, an official action must provide a rationale or show evidence tending to show inherency. *In re Robertson*, 169 F.3d 743, 745, 49 USPQ2d 1949, 1950–51 (Fed. Cir. 1999) states that:

“To establish inherency, the extrinsic evidence ‘must make clear that the missing descriptive matter is necessarily present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill. Inherency, however, may not be established by probability or possibilities. The mere fact that a certain thing may result from a given set of circumstances is not sufficient.’”

In this case, it is submitted that the references neither shows, nor gives assurance, that the characteristics found in the claims would be provided by the materials therein. Accordingly, it is respectfully submitted that this rejection should be withdrawn.

3. Section 103 rejections.

Claims 1-2, 4-6 and 48-52 stand rejected as obvious over US Patent No. 5786150 to **Hillman et al.** as evidenced by applicant's definitions on pages 11-12 of the specification. This rejection is respectfully traversed.

While the reference discusses the construction of antibodies to F₀ ATP synthase, the reference neither discloses nor suggests that antibodies be made to the region of ATP synthas that is inhibited by angiostatin. Accordingly, it is respectfully submitted that this rejection should be withdrawn.


Claims 1-2 and 4-5 stand rejected as obvious under 35 USC 103(a) over US Patent No. 5837682 to **Folkman et al.** as evidence by applicant's definitions on pages 11-12 of the specification. This rejection is respectfully traversed. The reference suggests administering antibodies specific for angiostatin to humans to **reduce** angiogenic inhibition (column 5, lines 20-22). The presently elected invention is concerned with anti-angiogenic antibodies. Accordingly, it is respectfully submitted that this rejection should be withdrawn.

Claims 1 and 7 stand rejected as obvious over **Hillman et al.** or **Folkman et al.** in view of US Patent No. 6056973 to **Allen et al.** It is respectfully submitted that this rejection is obviated for the same reasons as set forth above, and respectfully submitted that this rejection should be withdrawn.

Claims 1 and 7 stand rejected as obvious over **Hillman et al.** or **Folkman et al.** in view of US Patent No. 6025353 to **Masferrer et al.** It is respectfully submitted that this rejection is obviated for the same reasons as set forth above, and respectfully submitted that this rejection should be withdrawn.

It is respectfully submitted that this application is in condition for allowance, which action is respectfully requested.

Respectfully submitted,



Kenneth D. Sibley
Registration No. 31,665

Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, NC 27627
Telephone (919) 854-1400
Facsimile (919) 854-1401

Enclosure: Moser et al., PNAS

Endothelial cell surface F_1 - F_0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin

Tammy L. Moser^{*†}, Daniel J. Kenan^{*†}, Timothy A. Ashley^{*}, Julie A. Roy^{*}, Michael D. Goodman^{*}, Uma K. Misra^{*}, Dennis J. Cheek[‡], and Salvatore V. Pizzo^{*§}

^{*}Department of Pathology and [‡]Duke University School of Nursing, Duke University Medical Center, Durham, NC 27710

Edited by Irwin Fridovich, Duke University Medical Center, Durham, NC, and approved April 4, 2001 (received for review February 9, 2001)

Angiostatin blocks tumor angiogenesis *in vivo*, almost certainly through its demonstrated ability to block endothelial cell migration and proliferation. Although the mechanism of angiostatin action remains unknown, identification of F_1 - F_0 ATP synthase as the major angiostatin-binding site on the endothelial cell surface suggests that ATP metabolism may play a role in the angiostatin response. Previous studies noting the presence of F_1 ATP synthase subunits on endothelial cells and certain cancer cells did not determine whether this enzyme was functional in ATP synthesis. We now demonstrate that all components of the F_1 ATP synthase catalytic core are present on the endothelial cell surface, where they colocalize into discrete punctate structures. The surface-associated enzyme is active in ATP synthesis as shown by dual-label TLC and bioluminescence assays. Both ATP synthase and ATPase activities of the enzyme are inhibited by angiostatin as well as by antibodies directed against the α - and β -subunits of ATP synthase in cell-based and biochemical assays. Our data suggest that angiostatin inhibits vascularization by suppression of endothelial-surface ATP metabolism, which, in turn, may regulate vascular physiology by established mechanisms. We now have shown that antibodies directed against subunits of ATP synthase exhibit endothelial cell-inhibitory activities comparable to that of angiostatin, indicating that these antibodies function as angiostatin mimetics.

Tumor expansion beyond a prevascular size requires generation of new blood vessels, termed angiogenesis. As the tumor expands, vascular remodeling and continued angiogenesis is essential to support this growth (1–3). Inhibition of angiogenesis not only arrests tumor growth, but also results in tumor shrinkage to a prevascular size (4, 5). The regulation of angiogenesis is a complex process involving enzymatic and signal-transduction cascades that function in fibrinolysis, matrix remodeling, inflammation, hemodynamic control of oxygenation, and growth regulation (6, 7). The activation of these pathways produces many molecules with either proangiogenic or antiangiogenic properties. Folkman and colleagues (3, 8, 9) have hypothesized that the local balance between these various positive and negative factors determines the net tendency toward angiogenesis or angiostasis.

Critical to this angiogenic “set point” is the behavior of the cancer itself. Proangiogenic signals elaborated by tumor cells set into motion a series of highly regulated endothelial responses. The fibrinolytic system of plasminogen, its activators, and inhibitors plays a central role in the interface events that occur between endothelial and tumor cells (10). Plasmin is important enzymatically through its ability to activate matrix metalloproteinases (MMPs), which enable tumor cells to proteolytically degrade basement membrane barriers and metastasize (11, 12). Plasminogen and its activators bind to tumor cell membrane receptors, where plasmin is generated and signal transduction is triggered, promoting MMP-9 secretion (13, 14). However, further proteolytic cleavage of plasmin by both host and tumor cell proteinases produces additional fragments lacking proteolytic activity, some of which inhibit angiogenesis (15–17). These fragments, termed angiostatins, are among the most potent antiangiogenic substances currently known. All angiostatins

have in common the presence of one or more of the five kringle domains contained within plasminogen. The form used in the present study consists of human kringles 1–3, which inhibit proliferation and migration of cultured endothelial cells (18). Suppression of primary and metastatic tumor growth occurs in mice injected with purified angiostatin (15, 19, 20), with evidence of increased tumor cell apoptosis (21).

We previously identified a candidate angiostatin receptor, endothelial cell surface-associated F_1 - F_0 ATP synthase (hereafter referred to as ATP synthase), based on affinity purification of this enzyme's α - and β -subunits from human umbilical vein endothelial cell (HUVEC) plasma membranes over an angiostatin-Sepharose column (18). Supporting the identity of this receptor was the observation that polyclonal antibodies against the α -subunit of ATP synthase blocked angiostatin binding to HUVEC as well as its ability to inhibit endothelial cell proliferation. This initial study, however, did not demonstrate an intact, enzymatically active, surface-associated ATP synthase complex, nor did it assess whether angiostatin could block activity of this putative complex. In the current study, we demonstrate conclusively that all components forming the core catalytic complex of F_1 ATP synthase are present on the external endothelial cell surface. Moreover, we show that this enzyme is catalytically competent in the synthesis of ATP on the surface of endothelial cells. Finally, we show that both angiostatin and antibodies against the α - and β -subunits of ATP synthase inhibit activity of the surface-associated enzyme and the purified enzyme. Taken together, these data strongly support our original hypothesis that ATP synthase is the primary target for angiostatin on the surface of endothelial cells and further suggest that cell surface ATP metabolism is likely to play a central role in the endothelial cell response to angiostatin. The ability of angiostatin or antibodies to disrupt ATP production may render endothelial cells more vulnerable to hypoxic challenge in the microenvironment of a growing tumor and additionally may alter ATP-mediated signal transduction at the endothelial cell surface.

Materials and Methods

Confocal Microscopy. HUVECs were plated in microvascular endothelial cell growth medium (EGM-MV; Clonetics, San Diego) medium at 150,000 cells/ml on glass coverslips and allowed to adhere overnight. Cells were incubated at 4°C and washed with PBS before fixation in 2% paraformaldehyde solution. A control slide was permeabilized in 100% ethanol for 5 min at room temperature before fixation. All coverslips were

This paper was submitted directly (Track II) to the PNAS office.

Abbreviation: HUVEC, human umbilical vein endothelial cell.

[†]T.L.M. and D.J.K. contributed equally to this work.

[§]To whom reprint requests should be addressed at: Department of Pathology, Duke University Medical Center, P.O. Box 3712, Durham, NC 27710. E-mail: pizzo001@mc.duke.edu.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

incubated in 5% goat serum in Dulbecco's PBS, pH 7.4 (Life Technologies, Gaithersburg, MD) for 15 min and washed before coincubation with murine monoclonal anti- α ATP synthase (Molecular Probes) (1:100) and rabbit polyclonal antibody raised against the recombinant human β -subunit of ATP synthase (1:500) diluted in staining buffer (1% BSA/0.02% Tween 20/0.005 M EDTA/1% goat serum/1 \times PBS, pH 7.4). To verify surface staining, cells were incubated with murine monoclonal anti-CD31 (PharMingen). All cells were washed three times and incubated for 1 h in the dark at 4°C with goat anti-mouse IgG AF488 F(ab')₂ (Molecular Probes) (1:100), goat anti-rabbit IgG AF546 F(ab')₂ (Molecular Probes) (1:200), or goat anti-mouse IgG1 AF633 (1:100) in staining buffer. After the final washes, cells were visualized by using a Zeiss LSM-410 (Switzerland) confocal microscope at $\times 630$.

ELISA-Binding Studies. Binding studies were performed with purified F₁ subunit of bovine ATP synthase (20 μ g/ml) passively adsorbed onto polyvinylchloride microtiter 96-well, flat-bottom plates (Dynex Technologies, Chantilly, VA) as described (22). Briefly, plates were coated with protein in 50 μ l of 0.1 M Na₂CO₃, pH 9.6, and incubated for 2 h at 37°C. Nonspecific sites were blocked by incubating with PBS, pH 7.0, containing 1% BSA for 30 min at room temperature. Binding studies were performed with increasing amounts of angiotatin (0–0.5 mg/ml) added in a 50 μ l final volume for 1 h at 37°C. Plates were washed (0.1% Tween 20/PBS, pH 7.0) and incubated with anti-human angiotatin antibody (goat IgG) (R & D Systems) (1:200 dilution) overnight at 4°C. Plates were washed and incubated with anti-goat IgG peroxidase conjugate (Sigma) (1:7,500 dilution) for 1 h at 37°C. Plates were washed, 150 μ l of OPD substrate was added to each well, and the reaction was stopped with 25 μ l of H₂SO₄ (25%) before monitoring the absorbance at $\lambda = 492$ nm in a Molecular Devices SpectraMax Plus-384 plate reader. Control studies were performed in the absence of angiotatin to detect any nonspecific binding of secondary proteins. Isotype-specific controls were performed by using a goat antifibrinectin antibody (Sigma).

Purification of Bovine Heart F₁ ATP Synthase and F₁ Activity Assay. Fresh bovine heart mitochondria were obtained as described (23) and sonicated to yield submitochondrial particles (24). The F₁ portion was separated from membrane-bound F₀ by chloroform extraction. The aqueous layer was centrifuged at 105,000 \times g to remove particulate matter before purifying over an S300 gel-filtration column. The purified F₁ ATP synthase only exhibits activity in the reverse reaction (ATPase), because the forward reaction (ATP synthase) requires the F₁-F₀ holoenzyme correctly assembled into a membrane across which a proton gradient exists. ATPase activity was measured spectrophotometrically by monitoring at $\lambda = 340$ nm by coupling the production of ADP to the oxidation of NADH via pyruvate kinase and lactate dehydrogenase reactions as described (25).

Cell Surface ATP Assay. Quiescent, confluent HUVECs in 24-well plates were washed and equilibrated into DMEM/F-12 (HAM) 1:1 medium (Life Technologies) containing 10 mM potassium phosphate. Cells were treated with 1 μ M angiotatin or 0.1 mg/ml oligomycin for 1 h at 37°C. All cells then were incubated with 0.1 μ Ci ³²P_i and 0.1 μ Ci (50 μ M) [2,8-³H]-ADP (NEN) for 1 min. Supernatants were removed and centrifuged before assaying for ATP production by TLC or firefly luciferase assay.

ATP Generation by Bioluminescent Luciferase Assay. Aliquots (50 μ l) of cellular supernatants from cell surface ATP assays were analyzed by using the ATP bioluminescence assay kit (Sigma). In this firefly luciferin-luciferase reaction, only ATP is readily detected because the enzymatic reaction of firefly luciferase to

oxidize luciferin is specific for ATP relative to all other nucleotides. Samples were injected with the ATP assay mixture, and recordings were made in a LuminoskanRS (Labsystems, Franklin, MA) over a 10-s period. The response in a given sample or standard was quantified as area under the peak of the response and averaged for duplicate determinations. Data are expressed as picomoles of ATP produced per cell based on standards determined under the same conditions with each experiment. Angiotatin was prepared as described (26). Angiotatin did not interfere with the luciferin-luciferase assay, indicating that the effects of angiotatin are not an assay artifact (data not shown).

Dual-Label Radioactive TLC of ATP. Supernatants were obtained as described above. Cell pellets were obtained after washing wells with 1.0 ml of medium (as described above) and lysing with 1 M NaOH (100 μ l). Aliquots of supernatant (3 μ l) and cell pellet (10 μ l) were applied to microcrystalline polyethyleneimine-cellulose plates (Analtech) along with an authentic [γ -³²P]ATP standard (0.025 μ Ci). Plates were developed in 1.4 M LiCl for a distance of 15 cm (27). Dried spots containing [³²P]ATP, [³H]ATP, and [³H]ADP were detected by sodium iodide and phosphorimaging on a Storm 850 (Molecular Dynamics). Areas corresponding in R_f value to cochromatographed authentic [³²P]ATP standard were scraped off the plate, and their radioactivity was determined in a liquid scintillation analyzer (Packard). No ATP was detectable by TLC in the [³H]ADP preparation used for all experiments.

Cell Proliferation Assay. HUVECs were plated at a density of 5,000 cells per well in medium depleted of FCS overnight to allow the cells to become quiescent. Fresh medium containing 5% FCS, 10 ng/ml basic fibroblast growth factor, and 3 ng/ml vascular endothelial growth factor were added to the wells along with angiotatin (1.0 μ M), antibody directed against the recombinant human α -subunit of ATP synthase (1:10 dilution), antibody directed against the recombinant human β -subunit of ATP synthase (1:10 dilution), preimmune serum (1:10 dilution), or cycloheximide (10 μ g/ml). Cell density was measured after 24 h by using the CyQUANT Cell Proliferation Assay Kit (Molecular Probes) in a fluorometric plate reader (Molecular Devices). The absorbance values used to calculate the percentage of proliferation of the cells ranged from 1.24 or 1.00 for treated and 2.57 for untreated.

Results

α - and β -Subunits of ATP Synthase Colocalize on the Surface of HUVECs. Our previous studies demonstrated the presence of the α -subunit of ATP synthase on the surface of endothelial cells by immunofluorescence and flow cytometry (18). We now demonstrate extensive colocalization of the α - and β -subunits of ATP synthase on the endothelial cell surface by using confocal microscopy with a mAb specific for the α -subunit of ATP synthase and affinity-purified antibodies generated against the recombinant β -subunit of ATP synthase (Fig. 1C). The immunofluorescence occurs in two distinctive patterns. First, there are numerous fine punctate structures distributed over the entire cell surface, except where the bulging nucleus displaces the plasma membrane from the optical section. Second, each cell displays one or more irregular clusters of punctate structures, suggesting an organized distribution on the cell surface. The cells were fixed *in situ* before the addition of antibodies to eliminate antibody-capping artifacts. Parallel studies of immunolocalization between the α - and γ -subunits of ATP synthase showed virtually identical patterns of colocalization (data not shown).

Fluorescence in all images was determined to be cell surface-associated by three criteria. (i) Permeabilized cells (Fig. 1D) produced a dramatically different pattern characteristic of mitochondrial staining of ATP synthase. Endothelial cell mito-






Fig. 1. Colocalization of the α - and β -subunits of ATP synthase on the surface of HUVECs by immunostaining and confocal microscopy. (a) Nonpermeabilized HUVECs immunostained with a murine mAb specific for the α -subunit of ATP synthase. (b) The same cells immunostained with a rabbit polyclonal antiserum specific for the β -subunit of ATP synthase. (c) Composite colocalization images obtained by digital overlays of the above images. (d) Colocalization image obtained from cells permeabilized with ethanol (100%). Representative images are shown; $n = 26$.

chondria are characteristically tubular and reticular in pattern, with a perinuclear concentration as seen in Fig. 1D. (ii) Confocal optical sectioning along the z axis confirmed an apical concentration of antigen distribution characteristic of surface staining (Fig. 2A–D, discussed below). (iii) Costaining with a known endothelial cell surface marker, CD31, produced overlapping distributions in z axis optical sections, as would be expected for surface localization (Fig. 2C). Flow cytometry of primary HUVECs also was performed with cells determined to be nonpermeabilized by dye exclusion. These cells demonstrated cell surface expression of the α -subunit of ATP synthase (data not shown), confirming that the staining of ATP synthase that we detect is not due to permeabilization but rather to the presence of this enzyme on the cell surface.

The cell surface localization was investigated further by confocal microscopy comparing staining with CD31, an established endothelial cell surface marker, and the α -subunit of ATP synthase. Fig. 2E and F demonstrates CD31 and α -ATP synthase staining, respectively, and Fig. 2C shows the overlay of these two images. The image in Fig. 2C was taken at approximately the midpoint between the basal and apical surfaces of cultured endothelial cells and clearly shows a marginal distribution of the punctate structures containing ATP synthase along the periphery of the cells. Fig. 2A–D shows the same field of view in optical sections along the z axis, with A starting near the basal aspect and D ending near the apical aspect of the cultured cells. It is important to note that the apical surface would be equivalent to




Fig. 2. Surface localization of the α -subunits of ATP synthase and CD31 on nonpermeabilized HUVECs by immunostaining and confocal microscopy. (A–D) Confocal optical sections were taken along the z axis every $1.5 \mu\text{m}$. Each section is $\sim 0.6 \mu\text{m}$ in thickness. A series of z sections from a representative field is shown, starting with the basal surface in A and ending with the apical surface in D. (E) The same section shown in C; fluorescence from red channel only. (F) The same section shown in C; fluorescence from green channel only; $n = 3$.

the luminal surface if these cells were within the vasculature. Although confocal microscopy emphasizes structures within the optical plane of sectioning, structures that are above or below the plane of section also may be visualized if their staining is particularly intense. However, structures that are outside the confocal plane will display fuzzy margins, whereas structures within the focal plane will show sharp margins. This effect is seen with the α -ATP synthase staining. Examination of the sharp, green spots demonstrates that essentially all α -ATP synthase staining is confined to the cellular margins in subapical sections of nonpermeabilized cells (Fig. 2A–C). Moreover, α -ATP synthase exhibits a greater intensity of staining in the apical section (Fig. 2D), in which the confocal plane grazes the majority of the exposed apical surface, as would be expected for a surface-localized marker.

Angiostatin Binds to Bovine F_1 ATP Synthase. Human angiostatin bound to purified bovine F_1 ATP synthase passively adsorbed onto microtiter wells in a concentration-dependent manner (Fig. 3). Human and bovine ATP synthase are highly homologous, differing only by eight aa residues in the mature α -chains (SWISS-PROT accession nos. P25705 and P19483, respectively) and six residues in the mature β -chains (SWISS-PROT accession nos. P06576 and P00829, respectively). Similar results were obtained with purified bovine F_1 ATP synthase binding to immobilized angiostatin (data not shown). Microtiter wells coated with decreasing concentrations of purified bovine F_1 ATP synthase also showed concentration-dependent binding of angiostatin (data not shown). Background binding of angiostatin to BSA-coated wells gave values comparable to the baseline seen




Fig. 3. Binding of angiotensin to purified bovine F_1 ATP synthase. ELISA was used to determine concentration-dependent binding of angiotensin to a constant amount of F_1 ATP synthase. Each well was coated with 1 μ g of F_1 ATP synthase before addition of decreasing amounts of angiotensin. Control lane (—) shows binding of secondary antibody only ($n = 6$). (Inset) Apparent dissociation constants [$K_{d(app)}$] were determined from double-reciprocal plots of the binding data as shown in Fig. 3. Angiotensin bound to bovine F_1 ATP synthase with a $K_{d(app)}$ of 14.1 nM.

in Fig. 3 (compare 0 μ g/ml with 0.2 μ g/ml), indicating that angiotensin requires F_1 ATP synthase for efficient binding. Apparent dissociation constants [$K_{d(app)}$] were determined from double-reciprocal plots of the binding data as shown in Fig. 3. Inset: The $K_{d(app)}$ for angiotensin binding to purified F_1 ATP synthase is 14.1 nM. Although this suggests a 10-fold-higher affinity than our previously determined value for binding of angiotensin to the cell surface form of ATP synthase (18), it must be recognized that the holoenzyme associates with numerous other proteins on the cell surface and, thus, may be sterically hindered to a significant degree. In contrast, the purified F_1 subcomplex would not be subjected to steric hindrance by associated proteins and would be expected to exhibit an increased affinity for its ligands.

Angiotensin Inhibits Purified Bovine F_1 ATP Synthase Activity. Although the F_1 - F_0 ATP synthase holoenzyme efficiently catalyzes both the forward ATP synthase reaction and the reverse ATP hydrolysis reaction, the purified F_1 ATP synthase subcomplex catalyzes only the reverse reaction. The ATP hydrolytic activity of the purified bovine F_1 ATP synthase was measured by using a coupled enzymatic assay in which production of ADP is linked to oxidation of NADH via pyruvate kinase and lactate dehydrogenase (28). Thus, a decrease in the absorbance measured at $\lambda = 340$ nm indicates ATPase activity. Angiotensin completely inhibited purified ATPase activity, similar to a known F_1 inhibitor, NaN_3 (Fig. 4). Polyclonal antibodies directed against the recombinant α -, β -, and γ -subunits of ATP synthase also were tested. Both α - and β -subunit-specific ATP synthase polyclonal antibodies abolished ATPase activity. In contrast, the γ -subunit-specific ATP synthase antibody had no effect (data not shown). In addition, a commercial mAb specific for the α -subunit of ATP synthase (Molecular Probes) also inhibited activity. Preimmune, unrelated polyclonal, and unrelated mAbs used as controls had no effect on activity.

Surface-Associated ATP Synthase Is Catalytically Competent. The presence of the α -, β -, and γ -subunits of ATP synthase on the endothelial cell surface suggests that the entire catalytic complex is present. To test for functional activity, we incubated HUVECs with [3H]ADP, [^{32}P], and unlabeled phosphate (100 mM) and followed ATP production by analysis of supernatants on micro-




Fig. 4. Inhibition of purified F_1 ATP synthase by angiotensin. Purified F_1 ATP synthase activity was measured spectrophotometrically at $\lambda = 340$ nm by coupling the production of ADP to the oxidation of NADH via the pyruvate kinase and lactate dehydrogenase reaction, in which a decrease in the absorbance at $\lambda = 340$ nm indicates active protein (●) (28). Angiotensin (10 μ M) completely inhibited purified F_1 ATP synthase activity (○), comparable to a known F_1 ATP synthase inhibitor, NaN_3 (2%) (▲) and an enzyme-free control (▲). Polyclonal antibodies directed against the recombinant α -subunit of ATP synthase (500 μ g/ml) (▼) and β -subunit ATP synthase (700 μ g/ml) (▽) abolished ATPase activity. A mAb to the α -subunit of ATP synthase (25 μ g/ml) also inhibited activity (■). Control antibodies had no effect on activity (○, □). Representative data are shown; $n = 3$.

crystalline polyethyleneimine-cellulose TLC plates. ATP generation was detected within the first 15 s and reached maximal levels by 1 min. The possibility of ATP release from intracellular pools was discounted because the cells tested were intact, as evident by Trypan blue exclusion and lack of lactate dehydrogenase release (data not shown). Moreover, the ratio of [3H]ATP/[^{32}P]ATP remained constant at 1.56 ± 0.04 over the time measured, thus demonstrating that the ADP and P_i substrates used to form ATP were derived exclusively from the external medium. No labeled product was detectable within the cell pellets (data not shown), again confirming that the ATP was synthesized on the cell surface.

To determine whether angiotensin inhibits ATP synthesis on the endothelial cell surface, we measured ATP production in the extracellular medium by using a bioluminescence assay. This assay is highly specific for ATP, to the exclusion of all other nucleotides. ATP concentrations significantly more than basal levels were detected in the extracellular milieu, indicating that *de novo* ATP synthesis occurred on the cell surface (Table 1).

Table 1. Inhibition of ATP generation on the surface of HUVECs as measured by bioluminescent luciferase assay

Treatment applied to cultured HUVEC in the presence of 50 μ M ADP	Percent inhibition \pm SEM
Medium alone	0
Angiotensin (1 μ M)	81.0 \pm 6.0
Polyclonal α -ATP synthase (1.0 mg/ml)	64.8 \pm 3.2
Polyclonal β -ATP synthase (0.5 mg/ml)	56.8 \pm 5.8
Preimmune serum (1.0 mg/ml)	0 \pm 7.6
Oligomycin (50 μ g/ml)	83.5 \pm 4.5

Basal ATP levels in the assay medium (in the absence of ADP) produced bioluminescence signals equivalent to approximately 4% of the uninhibited levels in the presence of ADP. $n = 3$.




Fig. 5. Inhibition of ATP generation by angiotensin on the surface of HUVECs as measured by bioluminescent luciferase assay. ATP generation on the surface of HUVECs was inhibited in a dose-dependent manner in the presence of increasing concentrations of angiotensin. Representative data are shown; $n = 3$.

Release of intracellular ATP pools was excluded by the low level of ATP measured in the absence of ADP. Angiotensin inhibited ATP synthesis in a dose-dependent manner (Fig. 5). ATP synthesis was inhibited 81% by 1 μM angiotensin as shown in Table 1. Polyclonal antibodies against either the α - or β -subunits of ATP synthase inhibited cell surface production of ATP by 65% and 57%, respectively. In contrast, preimmune serum showed no inhibition. Oligomycin, a known inhibitor of the F_0 subcomplex, inhibited ATP synthesis by 84% under these conditions, confirming that the major activity assayed was a result of ATP synthase.

Inhibition of HUVEC Proliferation in the Presence of Angiotensin and Anti- β -ATP Synthase Antibodies. We previously showed that an antibody raised against the α -subunit of ATP synthase abrogated the antiproliferative effects of angiotensin in an endothelial cell-proliferation assay. In the present study, polyclonal antibodies raised against the β -subunit of ATP synthase inhibited endothelial cell proliferation 1.5- to 2-fold more effectively than angiotensin (Table 2). The antiproliferative effect of the β -subunit-specific antibody approached that of cycloheximide (80.9% and 100%, respectively). However, this effect is unlikely to represent a toxic response because the cellular morphology of the anti- β -subunit ATP synthase-treated cells was unchanged from that of untreated cells, in contrast to the obvious rounded morphology caused by cycloheximide (data not shown). The preimmune serum exhibited no effect on proliferation. These data suggest that antibodies directed against the β -subunit of

Table 2. Inhibition of HUVEC proliferation in the presence of angiotensin and anti- β -ATP synthase antibody as measured by CyQUANT

	Percent inhibition \pm SEM
Medium only	0 \pm 1.034
Angiotensin (1 μM)	57.2 \pm 1.16
Cycloheximide (10 $\mu\text{g/ml}$)	100 \pm 7.0
Polyclonal β -ATP synthase (100 $\mu\text{g/ml}$)	80.9 \pm 15.9
Preimmune serum (100 $\mu\text{g/ml}$)	0 \pm 1.7

$n = 3$.

ATP synthase act as angiotensin mimetics in both biochemical and cell-based assays of ATP synthase function.

Discussion

We previously demonstrated by affinity chromatography that the α - and β -subunits of ATP synthase constitute the major endothelial cell binding site for angiotensin (18). Our initial study used a polyclonal antiserum raised against the α -subunit of ATP synthase to detect cell surface subunits and to block binding and endothelial cell-inhibitory activity of angiotensin. In that study, we did not investigate whether the cell surface form of ATP synthase was functional or whether other ATP synthase subunits also were present on the cell surface. We now extend our initial study to show that ATP synthase is catalytically active on the endothelial cell surface and that angiotensin-mediated inhibition of this activity correlates with inhibition of proliferation. Moreover, we demonstrate that certain antibodies directed against the α - and β -subunits of ATP synthase also inhibit enzymatic activity and endothelial cell proliferation. These antibodies, therefore, appear to constitute functional mimetics of angiotensin.

In addition to angiotensin, there are known inhibitors of ATP synthase that exhibit antitumor effects including piceatannol (25) and resveratrol (29). Resveratrol inhibits the development of 7,12-dimethylbenz[*a*]anthracene-induced preneoplastic lesions and tumor growth (30). Piceatannol was shown to inhibit tumor cell growth by inhibition of protein-tyrosine kinases (25). That both of these antitumor compounds inhibit ATP synthase suggests a relationship between the endothelial cell antiproliferative effects of angiotensin and cell surface-associated ATP synthesis.

The generally accepted concept that ATP synthesis is strictly an intracellular process now appears questionable. It is well established that both nucleosides and nucleotides act as extracellular-signaling molecules (31, 32). Indeed, the extracellular role of nucleotides in regulating multicellular communication is widely conserved in eukaryotic evolution (33). Extracellular receptors for ATP exist as both ion channels (P2X) and G protein-coupled receptors (P2Y) that are ubiquitous to all mammalian tissues (32). A recent study demonstrates that ATP release by physical or chemical means contributes to the set point of cellular-signaling pathways coupled to P2Y receptors (34). In the cardiovascular system, adenosine released from myocytes maintains blood flow to ischemic areas of the heart (35), and ATP may play a role in the moment-to-moment regulation of cardiac blood flow in nonpathological states (36). Endothelial cells release ATP in response to stimuli such as shear stress and vasoactive agonists including ATP (37, 38).

The availability of significant amounts of ATP on the surface of endothelial cells may provide several mechanisms to promote endothelial cell proliferation and increases in tumor blood flow. We originally hypothesized that ATP generated on the cell surface is transported into the cell, providing a source of energy for endothelial cells in the tumor microenvironment, where vascular pO_2 levels can be as low as 12 ± 3 mmHg in tumor central vessels (39). A functional test of this hypothesis remains to be performed, and the present study does not address this issue. An alternate hypothesis is that surface-generated ATP is available to act through the P2Y receptor to activate Ca^{2+} -dependent-signaling cascades, which increase DNA synthesis (32). This would tend to promote endothelial cell proliferation in the tumor environment. Our finding that angiotensin suppresses the generation of cell surface-associated ATP suggests that this antiangiogenesis factor might regulate one or more mechanisms that promote tumor vascularization.

Our immunolocalization data show that the α -, β -, and γ -subunits of ATP synthase are present on the endothelial cell surface, where they colocalize extensively. These subunits represent the minimal components required for efficient ATPase

catalytic activity and strongly suggest that the cell surface form of ATP synthase is similar to the mitochondrial form. Moreover, cell surface ATP synthase is present in discrete foci, indicating structural organization of the enzyme complex. We also have detected numerous other mitochondrial matrix enzymes that colocalize with ATP synthase into these discrete foci on the endothelial cell surface, but mitochondrial outer-membrane markers were not detected (data not shown). These findings suggest that a highly complex energy-production apparatus exists on the endothelial cell surface.

Although the mechanism of angiostatin action on endothelial cells remains largely unknown, our data strongly suggest that angiostatin operates through inhibition of the enzymatic activity of cell surface ATP synthase. Data supporting this interpretation include concordance of inhibitory activities of angiostatin, known small molecule inhibitors of ATP synthase, and antibodies specific for ATP synthase subunits in binding and biochemical assays by using purified bovine enzyme. There are also similar effects of angiostatin and subunit-specific antibodies in the inhibition of ATP production on the surface of cultured human endothelial cells. It should be noted that existing small molecule inhibitors cannot be used in this assay because they also inhibit the mitochondrial form of ATP synthase, whereas neither angiostatin nor the subunit-specific antibodies cross the cell

membrane. Finally, angiostatin and anti- β -subunit antibodies show similar ability to inhibit proliferation of cultured human endothelial cells.

Collectively, these data suggest a steric hindrance model of ATP synthase inhibition by angiostatin. ATP synthase couples proton flux across a membrane to rotation of the γ -subunit, which, in turn, induces cyclical conformational changes in the catalytic β -subunits (40). These conformational changes, required for conversion of ADP to ATP, can be blocked by any compound that either inhibits rotation of the γ -subunit or locks the conformation of the α - or β -subunits. It is well established that binding of specific antibodies can lock the conformation of flexible antigens. Thus, we propose that both angiostatin and certain antibodies to the α - or β -subunits of ATP synthase inhibit the enzyme by blocking conformational changes of the enzyme complex required for ATP synthesis or hydrolysis. This observation provides a great deal of hope that functional mimetics of angiostatin can be derived by developing mAbs against the α - or β -subunits of ATP synthase. Such antibodies likely would be far easier to produce and administer than angiostatin and may offer significant advances in antiangiogenic therapy of cancer and other proliferative diseases.

We thank Steve Conlon for confocal image preparation.

- Folkman, J. (1997) in *Cancer Medicine*, eds. Holland, J. F., Frei, E., Bast, R., Kufe, D., Morton, D., & Weichselbaum, R. (Williams & Wilkins, Baltimore), Vol. 1, pp. 181–204.
- Gulloni, P. M. (1978) *J. Natl. Cancer Inst.* 61, 639–643.
- Hanahan, D. & Folkman, J. (1996) *Cell* 86, 353–364.
- Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) *Nature* (London) 339, 58–61.
- Folkman, J. (1971) *N. Engl. J. Med.* 285, 1182–1186.
- Kerbel, R. S. (2000) *Carcinogenesis* 21, 505–515.
- Carmeliet, P. (1999) *Nature* (London) 401, 657–658.
- Bouck, N., Stellmach, V., & Hsu, S. C. (1996) *Adv. Cancer Res.* 69, 135–174.
- Hanahan, D. & Weinberg, R. A. (2000) *Cell* 100, 57–70.
- Folkman, J. (2000) *J. Natl. Cancer Inst.* 92, 94–95.
- Liotta, L. A. (1992) *Sci. Am.* 266, 54–63.
- DeClerck, Y. A. & Laug, W. E. (1996) *Enzyme Protein* 49, 72–84.
- Gonzalez-Gronow, M., Gawdi, G., & Pizzo, S. V. (1994) *J. Biol. Chem.* 269, 4360–4366.
- Gonzalez-Gronow, M., Grenett, H. E., Weber, M. R., Gawdi, G., & Pizzo, S. V. (2001) *Biochem. J.* 355, 397–407.
- O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., & Folkman, J. (1994) *Cell* 79, 315–328.
- Gately, S., Twardowski, P., Stack, M. S., Patrick, M., Boggio, L., Cundiff, D. L., Schnaper, H. W., Madison, L., Volpert, O., Bouck, N., et al. (1996) *Cancer Res.* 56, 4887–4890.
- Gately, S., Twardowski, P., Stack, M. S., Cundiff, D. L., Grella, D., Castellino, F. J., Enghild, J., Kwaan, H. C., Lee, F., Kramer, R. A., et al. (1997) *Proc. Natl. Acad. Sci. USA* 94, 10868–10872.
- Moser, T. L., Stack, M. S., Asplin, I., Enghild, J. J., Hojrup, P., Everitt, L., Hubchak, S., Schnaper, H. W., & Pizzo, S. V. (1999) *Proc. Natl. Acad. Sci. USA* 96, 2811–2816.
- O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) *Nat. Med.* 2, 689–692.
- Drixler, T. A., Rinkes, I. H., Ritchie, E. D., van Vroonhoven, T. J., Gebbink, M. F., & Voest, E. E. (2000) *Cancer Res.* 60, 1761–1765.
- Claesson-Welsh, L., Welsh, M., Ito, N., Anand-Apte, B., Soker, S., Zetter, B., O'Reilly, M., & Folkman, J. (1998) *Proc. Natl. Acad. Sci. USA* 95, 5579–5583.
- Moser, T. L., Enghild, J. J., Pizzo, S. V., & Stack, M. S. (1993) *J. Biol. Chem.* 268, 18917–18923.
- Johnson, D. & Lardy, H. (1967) *Methods Enzymol.* 10, 94–96.
- Li, S. G., Gui, L. L., Lin, Z. H., Wan, Z. L., Chang, W. R., & Liang, D. C. (1996) *Biochem. Mol. Biol. Int.* 40, 479–486.
- Zheng, J. & Ramirez, V. D. (1999) *Biochem. Biophys. Res. Commun.* 261, 499–503.
- Soltrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T. E., & Magnusson, S. (1978) *Progress in Chemical Fibrinolysis and Thrombolysis* (Raven, New York).
- Kirchner, J. G. (1978) *Techniques of Chemistry in Thin Layer Chromatography* (Wiley, New York).
- Zheng, J. & Ramirez, V. D. (1999) *Eur. J. Pharmacol.* 368, 95–102.
- Zheng, J. & Ramirez, V. D. (2000) *Br. J. Pharmacol.* 130, 1115–1123.
- Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) *Science* 275, 218–220.
- Hoyle, C. H. V. & Burnstock, G. (1991) *Adenosine in the Nervous System* (Academic, London).
- Ralevic, V. & Burnstock, G. (1998) *Pharmacol. Rev.* 50, 413–492.
- Soderbom, F. & Loomis, W. F. (1998) *Trends Microbiol.* 6, 402–406.
- Ostrom, R. S., Gregorian, C., & Insel, P. A. (2000) *J. Biol. Chem.* 275, 11735–11739.
- Berne, R. M. (1985) *Methods in Pharmacology* (Plenum, New York).
- Buxton, I. L. O. & Cheek, D. J. (1995) *Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology* (Kluwer, New York).
- Yang, S., Cheek, D. J., Westfall, D. P., & Buxton, I. L. (1994) *Circ. Res.* 74, 401–407.
- Bodin, P. & Burnstock, G. (1996) *J. Cardiovasc. Pharmacol.* 27, 872–875.
- Dewhirst, M. W., Ong, E. T., Klitzman, B., Secomb, T. W., Vinuya, R. Z., Dodge, R., Brizel, D., & Gross, J. F. (1992) *Radiat. Res.* 130, 171–182.
- Boyer, P. D. (1997) *Annu. Rev. Biochem.* 66, 717–749.

